3 Hot Picks For February: AstraZeneca plc, BG Group plc, Rolls-Royce Holding PLC?

Will results from AstraZeneca plc (LON: AZN), BG Group plc (LON: BG) and Rolls-Royce Holding PLC (LON: BG) turn up bargains?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

What a dreadful January it’s been! With oil plunging below $30 a barrel at one point, and economic news from China getting worse, the FTSE 100 dipped as low as 5,640 points on 20 January — a massive 9.6% down on its end-of-2015 closing price!

Still, things are recovering cautiously, and with about half a day of January still to go the top index is back up to 5,980 points. And when markets are depressed, that means bargains, right?

Pharma recovery

Look at AstraZeneca (LSE: AZN), whose shares have lost 9% over the past 12 months, to 4,382p. How does the price of oil and Chinese economic woes affect AstraZeneca’s long-term pharmaceuticals business? Not at all!

AstraZeneca has been in the process of focusing on its core businesses and beefing up its drugs development pipeline ever since new boss Pascal Soriot took the helm in October 2012, and we’re not expecting a return to earnings growth until 2017 at the earliest. On 4 February, we should have full-year results, providing the latest news on the firm’s rejuvenation strategy.

Things looked very stable at third-quarter time, and we’ve also seen quite a number of promising milestones in drug development along the way — Q3 R&D costs were up 18%, “reflecting the recent start of key Oncology trials“.

Meanwhile, AstraZeneca is still nicely profitable, on a P/E of 15.5 and offering a likely 4.2% dividend yield.

Takeover boost

We should have full-year results from BG Group (LSE: BG) on 5 February, but they’ll take a back seat to the ongoing takeover from Royal Dutch Shell. Originally revealed back in April 2015 before the oil price slide had really set in, the plan was put to the vote this week and both sets of shareholders have voiced their approval — Shell on Wednesday and BG on Thursday.

BG’s share price fell back from its initial boost as falling oil raised fears that Shell was overpaying and that the merger would be called off or the terms changed, but we’ve seen a 16% recovery to 1,040p, which is largely in line with the Shell offer.

Mergers and acquisitions were always a big possibility after the oil price set asset values tumbling, and in this case I think BG shareholders are enjoying the better deal.

Engineering boost

Rolls-Royce Holdings (LSE: RR) has been through tough times, with its shares losing half their value since last April’s peak, to 540p. The cause was a series of profit warnings due to very tough trading conditions, and the company is firmly in turnaround mode right now.

Full-year results are due on 12 February, after a third-quarter update warned that “Further market headwinds increase uncertainty for 2016“. At the time, outlook for the full year was adjusted to the lower end of previous guidance, though I think that might still turn out to be optimistic.

If results are better than expected, we could see an uptick in the share price, but with EPS already forecast to drop by 43% in 2016 to put the shares on a forward P/E of 18, I wouldn’t be buying now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Royal Dutch Shell. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

1 FTSE dividend stock I’d put 100% of my money into for passive income!

If I could invest in just one stock to generate a regular passive income stream, I'd choose this FTSE 100…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

Forecasts are down, but I see a bright future for FTSE 100 dividend stocks

Cash forecasts for UK dividend stocks are falling... time to panic! Actually, no. I reckon the future has never looked…

Read more »

Young female analyst working at her desk in the office
Investing Articles

Down 13% in April, AIM stock YouGov now looks like a top-notch bargain

YouGov is an AIM stock that has fallen into potential bargain territory. Its vast quantity of data sets it up…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Beating the S&P 500? I’d buy this FTSE 250 stock for my Stocks and Shares ISA

Beating the S&P 500's tricky, but Paul Summers is optimistic on this FTSE 250 stock's ability to deliver based on…

Read more »

Passive and Active: text from letters of the wooden alphabet on a green chalk board
Investing Articles

2 spectacular passive income stocks I’d feel confident going all in on

While it's true that diversification is key when it comes to safe and reliable investing, these two passive income stocks…

Read more »

Investing Articles

The easyJet share price is taking off. I think it could soar!

The easyJet share price is having a very good day. Paul Summers takes a look at the latest trading update…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

9 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

As the Rentokil share price dips on Q1 news, I ask if it’s time to buy

The Rentokil Initial share price has disappointed investors in the past 12 months. Could this be the year we get…

Read more »